David (Lizhi) Yu
About David (Lizhi) Yu
David (Lizhi) Yu is the Associate Director of Precision Medicine and Translational Medicine at Bristol Myers Squibb in Boston, Massachusetts, with extensive experience in molecular assays and clinical testing.
Title
David (Lizhi) Yu holds the position of Associate Director, Precision Medicine and Translational Medicine at Bristol Myers Squibb in Boston, Massachusetts, United States.
Professional Background
David (Lizhi) Yu has held various significant positions across leading biomedical organizations. At Celgene, he was a Senior Scientist in Precision Medicine and Translational Medicine from 2018 to 2020. Prior to that, he worked at Juno Therapeutics, Inc. as a Strategic Lead and Senior Scientist in CAR-T therapy CDx assay development from 2017 to 2018. His tenure as Group Lead at Genocea Biosciences lasted from 2015 to 2017. Additionally, David served as Assay Development Lead and Principal Scientist at HTG Molecular Diagnostics from 2013 to 2014 and as Senior Scientist at RainDance Technologies from 2012 to 2013. He also contributed to Beckman Coulter as Assay Lead from 2006 to 2012 and was a Research Scientist at The University of Arizona from 2000 to 2006.
Education and Expertise
David (Lizhi) Yu achieved a Doctor of Philosophy (PhD) in Hematology and Oncology from Shanghai Jiao Tong University, completing his studies from 1995 to 1998. He also holds a Master of Science (MS) in Clinical Medicine from Jilin University, which he obtained between 1988 and 1995. His academic background has laid a solid foundation for his expertise in precision medicine and translational medicine.
Achievements in Molecular Assay Development
David (Lizhi) Yu has significantly contributed to the field of molecular assays. He led the development of multiplex real-time quantitative PCR assays for pathogens such as Herpes Simplex Virus, Chlamydia trachomatis, and Streptococcus pneumoniae. Additionally, he optimized and implemented a viral DNA extraction and testing pipeline capable of processing 3000 samples per week with a 95% or higher first-pass rate. His work has ensured efficient and effective clinical testing processes.
Clinical Trial Contributions
David (Lizhi) Yu has been instrumental in accomplishing clinical testing for several multi-stage Phase 2 and Phase 2b vaccine clinical trials, managing the analysis, documentation, quality control, and data submission for approximately 140,000 samples. His contributions have been pivotal in advancing vaccine efficacy testing and ensuring robust data management in clinical environments.